🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Pharmacokinetic

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus NCT06964087Phase 25 sites📍 Birmingham📍 Walnut Creek📍 Aurora Op-T LLC · Tests: OPT101, OPT101 Placebo to Match (PTM) Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma NCT07237425Phase 13 sites📍 Taipei📍 New Taipei City📍 Taipei Glonova Pharma Co., Ltd · Tests: Ronkyla Plus, Placebo, Kybella Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin NCT05069688Phase 11 site📍 Ibadan Brigham and Women's Hospital · Tests: rifampicin A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours NCT06682780Phase 1, Phase 21 site📍 Shanghai LaNova Medicines Limited · Tests: LM-2417, Docetaxel, Toripalimab/Tirelizumab, Carboplatin, Niraparib A Comparison of Fisetin Kinetics in Young and Old Adults NCT06796374NA1 site📍 Greifswald University Medicine Greifswald · Tests: Fisetin - Fasted condition, Fisetin - Fed condition Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants NCT07512427Phase 1, Phase 21 site📍 Miami OPKO Health, Inc. · Tests: OPK-88006, Placebo UmbrelLACT Study: Clinical Lactation Study on the Exposure to Medicines Via Human Milk NCT06042803n/a1 site📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: Human milk collection, Optionally: maternal blood sample, Optionally: child blood sample A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors NCT07110883Phase 12 sites📍 Harbin📍 Shanghai CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6023 A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma NCT07477587Phase 184 sites📍 Springdale📍 Jacksonville📍 Margate Shanghai Henlius Biotech · Tests: HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd PM534 Administered Intravenously to Patients With Advanced Solid Tumors NCT05835609Phase 13 sites📍 Barcelona📍 Madrid📍 Madrid PharmaMar · Tests: PM534 A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors NCT07229898Phase 14 sites📍 Harbin📍 Jinan📍 Shanghai Henan Genuine Biotech Co., Ltd. · Tests: GEN-725 tablets Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors NCT05631964Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1 " Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation " NCT06602557Phase 21 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Amikacin, Standard of care To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers NCT07514780Phase 11 site📍 Seoul JW Pharmaceutical · Tests: JW0061 SAD, JW0061 MAD, Placebo A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors NCT07744763Phase 1, Phase 21 site📍 Shanghai CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6041 Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment NCT06374485Phase 11 site📍 Hong Kong Lee's Pharmaceutical Limited · Tests: AU409 Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors NCT07145255Phase 1, Phase 27 sites📍 San Francisco📍 Grand Rapids📍 East Brunswick MBrace Therapeutics · Tests: ADC JMT106 Injection in the Treatment of Advanced Solid Tumors NCT07275073Phase 11 site📍 Zhejiang Shanghai JMT-Bio Inc. · Tests: JMT106 Injection A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M09D1 A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors NCT06533332Phase 15 sites📍 Ryde📍 Sydney📍 Westmead EtiraRx Australia Pty Ltd · Tests: ERX-315 EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors NCT07163325Phase 111 sites📍 Brussels📍 Brussels📍 Ghent Epics Therapeutics · Tests: EP102 A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers NCT07682948Phase 11 site📍 Anyang Korea United Pharm. Inc. · Tests: Investigational Product 1, Investigational Product 2, Investigational Product 1 + Investigational Product 2 A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors NCT07591155Phase 11 site📍 Tianjin Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-ARC002 A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation NCT07231068Phase 1, Phase 25 sites📍 Beijing📍 Beijing📍 Guangzhou Henan Genuine Biotech Co., Ltd. · Tests: Dositinib mesylate tablets A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor NCT05262491Phase 16 sites📍 Beijing📍 Nanchang📍 Jinan Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM) NCT06975618Phase 1, Phase 215 sites📍 Beijing📍 Beijing📍 Fuzhou Haihe Biopharma Co., Ltd. · Tests: CYH33, Placebo Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants NCT07258745Phase 11 site📍 Warsaw Chong Kun Dang Pharmaceutical · Tests: SKYRIZI, SKYRIZI, CKD-704 A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors NCT04794972Phase 16 sites📍 Beijing📍 Chongqing📍 Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. · Tests: GNC-039 Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy NCT04113382Phase 1, Phase 24 sites📍 Mobile📍 San Diego📍 Baltimore Ferring Pharmaceuticals · Tests: CLENPIQ, MIRALAX, SENNA A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity NCT07437079Phase 11 site📍 Lenexa Novo Nordisk A/S · Tests: NNC6989-0001, Placebo (NNC6989-0001)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy